Cardiol Therapeutics (TSE:CRDL) Sets New 12-Month High – What’s Next?

Cardiol Therapeutics Inc. (TSE:CRDL)’s share price reached a new 52-week high during trading on Thursday . The company traded as high as C$2.36 and last traded at C$2.30, with a volume of 216020 shares changing hands. The stock had previously closed at C$2.12.

Cardiol Therapeutics Stock Performance

The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of C$280.11 million, a price-to-earnings ratio of -6.23 and a beta of 0.27. The stock’s 50 day moving average price is C$1.63 and its two-hundred day moving average price is C$1.63.

Cardiol Therapeutics (TSE:CRDL) last announced its quarterly earnings data on Wednesday, August 12th. The company reported C($0.05) EPS for the quarter. On average, analysts forecast that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.